Table 5.
Comparison of Changes in Microflora Among Patients Who Achieved Sustained Cure of Clostridium difficile Infection With Changes Among Patients Who Achieved Cure But Had Subsequent Recurrence
| Log10 CFU/g Feces ± SD |
||||
|---|---|---|---|---|
| Patients With Sustained Cure |
Patients With Recurrence |
|||
| Day 0 | Day 10 | Day 0 | Day 10 | |
| Bacteroides group | ||||
| Vancomycin | 7.60 ± 2.21 | 5.26 ± 0.91a | 8.40 ± 2.01 | 4.37 ± 0.39 |
| Fidaxomicin | 8.52 ± 1.53b | 9.33 ± 1.30c | 5.76 ± 1.94 | 7.00 ± 2.33 |
| Prevotella species | ||||
| Vancomycin | 7.62 ± 2.17 | 5.50 ± 0.92d | 8.11 ± 1.99 | 4.43 ± 0.67 |
| Fidaxomicin | 8.11 ± 1.66 | 8.84 ± 1.19e | 5.26 ± 1.96 | 6.57 ± 2.20 |
| Clostridium coccoides group | ||||
| Vancomycin | 7.89 ± 1.58 | 4.67 ± 0.72 | 8.46 ± 0.51 | 4.95 ± 1.30 |
| Fidaxomicin | 8.17 ± 0.71 | 8.49 ± 0.55 | 7.21 ± 1.77 | 6.80 ± 2.77 |
Ten patients in the vancomycin group and 10 in the fidaxomicin achieved sustained cure, whereas 10 in the vancomycin group and 5 in the fidaxomicin group had recurrence. Values were determined on the basis of quantitative real-time polymerase chain reaction. Patients who experienced recurrence had lower counts of Bacteroides and Prevotella organisms. Fidaxomicin-treated patients with recurrence appeared to have greater reductions in Bacteroides counts at study entry.
Abbreviation: CFU, colony-forming unit.
a P < .03, compared with day 10 values for patients with recurrence.
b P = .03, compared with day 10 values for patients with recurrence.
c P = .08, compared with day 10 values for patients with recurrence.
d P = .007, compared with day 10 values for patients with recurrence.
e P = .11, compared with day 10 values for patients with recurrence.